1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Meningococcal Meningitis - Pipeline Review, H1 2014

Meningococcal Meningitis - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 62 pages

Meningococcal Meningitis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Meningococcal Meningitis - Pipeline Review, H1 2014’, provides an overview of the Meningococcal Meningitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meningococcal Meningitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meningococcal Meningitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meningococcal Meningitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Meningococcal Meningitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Meningococcal Meningitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Meningococcal Meningitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Meningococcal Meningitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Meningococcal Meningitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Meningococcal Meningitis - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Meningococcal Meningitis Overview 7
Therapeutics Development 8
Pipeline Products for Meningococcal Meningitis - Overview 8
Pipeline Products for Meningococcal Meningitis - Comparative Analysis 9
Meningococcal Meningitis - Therapeutics under Development by Companies 10
Meningococcal Meningitis - Therapeutics under Investigation by Universities/Institutes 12
Meningococcal Meningitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Meningococcal Meningitis - Products under Development by Companies 17
Meningococcal Meningitis - Products under Investigation by Universities/Institutes 18
Meningococcal Meningitis - Companies Involved in Therapeutics Development 19
Novartis AG 19
Pfizer Inc. 20
GlycoVaxyn AG 21
JN-International Medical Corporation 22
Beijing Tiantan Biological Products Co., Ltd. 23
Beijing Minhai Biotechnology Co., Ltd 24
Meningococcal Meningitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
PF-05212366 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Meningococcal (A,C,Y and W135) Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
meningococcal group B vaccine (rDNA, component, adsorbed) - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
NmVac4-ACYW135 DT - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Meningococcal Group B Meningitis Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
MenX Capsular Polysaccharide Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Meningococcal A+C Conjugate Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Meningococcal ACWY Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Polysaccharide Meningitis B Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Meningococcal Meningitis - Recent Pipeline Updates 49
Meningococcal Meningitis - Dormant Projects 52
Meningococcal Meningitis - Product Development Milestones 53
Featured News and Press Releases 53
Mar 20, 2014: Pfizer's Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 53
Feb 26, 2014: Bexsero: First Vaccine to Prevent Meningococcal Serogroup B (MenB) Now Available in Canada 54
Feb 24, 2014: Novartis provides second US university with Bexsero to help protect students and staff against potentially deadly meningitis B disease 54
Dec 09, 2013: Health Canada Approves Bexsero, the First Vaccine Available to Prevent Meningococcal Serogroup B 55
Dec 09, 2013: Novartis supplies MenB vaccine, Bexsero, to Princeton University to help protect students from potentially deadly outbreak 56
Nov 18, 2013: National Meningitis Association Supports the Collaborative Public Health Effort at Princeton University in Response to Outbreak 57
Aug 15, 2013: Novartis' Bexsero vaccine receives Australian approval for MenB disease 58
Jul 24, 2013: UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero vaccine 58
Jul 24, 2013: UK Panel Recommends Against Inclusion Of Novartis' Bexsero In Vaccination Programme 59
Jan 22, 2013: Novartis Receives EU Approval For First Meningitis B Vaccine Bexsero 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables

Number of Products under Development for Meningococcal Meningitis, H1 2014 8
Number of Products under Development for Meningococcal Meningitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Meningococcal Meningitis - Pipeline by Novartis AG, H1 2014 19
Meningococcal Meningitis - Pipeline by Pfizer Inc., H1 2014 20
Meningococcal Meningitis - Pipeline by GlycoVaxyn AG, H1 2014 21
Meningococcal Meningitis - Pipeline by JN-International Medical Corporation, H1 2014 22
Meningococcal Meningitis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 23
Meningococcal Meningitis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Assessment by Combination Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Meningococcal Meningitis Therapeutics - Recent Pipeline Updates, H1 2014 49
Meningococcal Meningitis - Dormant Projects, H1 2014 52

List of Figures

Number of Products under Development for Meningococcal Meningitis, H1 2014 8
Number of Products under Development for Meningococcal Meningitis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Products, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Meningitis - Market Insights, Epidemiology and Market Forecast-2023

Meningitis - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Meningitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global and Chinese Meningococcal Polysaccharide Vaccine Industry, 2016 Market Research Report

Global and Chinese Meningococcal Polysaccharide Vaccine Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • December 2016
  • by Prof Research

The ’Global and Chinese Meningococcal Polysaccharide Vaccine Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Meningococcal Polysaccharide ...

Global and Chinese Meningococcal Conjugate Industry, 2016 Market Research Report

Global and Chinese Meningococcal Conjugate Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • December 2016
  • by Prof Research

The ’Global and Chinese Meningococcal Conjugate Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Meningococcal Conjugate industry ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.